Powder: -20°C for 3 years | In solvent: -80°C for 1 year
WNK463 是口服有活性的 WNK 激酶抑制剂,能够抑制 WNK1 (IC50:5 nM)、WNK2 (IC50:1 nM)、WNK3 (IC50:6 nM)及 WNK4 (IC50:9 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,330 | 现货 | ||
25 mg | ¥ 2,820 | 现货 | ||
50 mg | ¥ 4,250 | 现货 | ||
100 mg | ¥ 5,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 913 | 现货 |
产品描述 | WNK463 is a pan-WNK-kinase inhibitor. It effectively inhibits the in vitro kinase activity of all four WNK family members (WNK1/2/3/4). |
靶点活性 | WNK4:9 nM, WNK1:5nM, WNK3:6nM, WNK2:1nM |
体外活性 | WNK463 potently inhibited the in vitro kinase activity of all four WNK family members (WNK1, WNK2, WNK3, and WNK4). WNK463 also inhibited WNK1-catalyzed phosphorylation of the native WNK substrate, oxidative stress response 1 (OSR1) in a biochemical assay and in human embryonic kidney 293 (HEK293) cells that express exogenous OSR1 and that are activated by sorbitol-mediated osmotic stress[1]. |
体内活性 | In rodent models of hypertension, WNK463 affects blood pressure and body fluid and electrolyte homeostasis. WNK463 is orally bioavailable in C57BL/6 mice (100%) and Sprague Dawley rats (74%), with a half-life of 3.6 and 2.1 h, respectively. In spontaneously hypertensive rats (SHRs), WNK463 administered orally (p.o.) at 1, 3, or 10 mg per kg body weight (mg/kg) p.o. achieved maximum plasma concentration (Cmax) values of 88, 441, and 1,170 nM, respectively. These exposures produced dose-dependent decreases in blood pressure and simultaneous increases in heart rate in conscious SHRs. Moreover, WNK463 produced significant and dose-dependent increases in urine output as well as urinary sodium and potassium excretion rates. Orally administered WNK463 also significantly decreased blood pressure in these hypertensive mice. WNK463 elicited in vivo cardiovascular and renal effects through WNK kinase inhibition[1]. |
分子量 | 463.46 |
分子式 | C21H24F3N7O2 |
CAS No. | 2012607-27-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 85 mg/mL (183.4 mM)
DMSO: 85 mg/mL (183.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1577 mL | 10.7884 mL | 21.5768 mL | 53.9421 mL |
5 mM | 0.4315 mL | 2.1577 mL | 4.3154 mL | 10.7884 mL | |
10 mM | 0.2158 mL | 1.0788 mL | 2.1577 mL | 5.3942 mL | |
20 mM | 0.1079 mL | 0.5394 mL | 1.0788 mL | 2.6971 mL | |
50 mM | 0.0432 mL | 0.2158 mL | 0.4315 mL | 1.0788 mL | |
100 mM | 0.0216 mL | 0.1079 mL | 0.2158 mL | 0.5394 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
WNK463 2012607-27-9 Cell Cycle/Checkpoint Metabolism Serine/threonin kinase Ser/Thr Protease inhibit Serine proteases Inhibitor Serine endopeptidases Threonine proteases WNK-463 WNK 463 inhibitor